| Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates X Gu, Q Ebrahem, RZ Mahfouz, M Hasipek, F Enane, T Radivoyevitch, ... The Journal of clinical investigation 128 (10), 4260-4279, 2018 | 108 | 2018 |
| Decitabine-and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network X Gu, R Tohme, B Tomlinson, N Sakre, M Hasipek, L Durkin, C Schuerger, ... Leukemia 35 (4), 1023-1036, 2021 | 69 | 2021 |
| Serum amyloid A1 and tumor necrosis factor-alpha alleles in Turkish familial Mediterranean fever patients with and without amyloidosis N Akar, M Hasipek, E Akar, M Ekim, F Yatçinkaya, N Clakar Amyloid 10 (1), 12-16, 2003 | 65 | 2003 |
| A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms Y Guan, AD Tiwari, JG Phillips, M Hasipek, DR Grabowski, S Pagliuca, ... Blood cancer discovery 2 (2), 146-161, 2021 | 45 | 2021 |
| Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia Y Guan, EF Greenberg, M Hasipek, S Chen, X Liu, CM Kerr, D Gackowski, ... Communications biology 3 (1), 493, 2020 | 33 | 2020 |
| Multiple myeloma therapy: emerging trends and challenges D Dima, D Jiang, DJ Singh, M Hasipek, HS Shah, F Ullah, J Khouri, ... Cancers 14 (17), 4082, 2022 | 29 | 2022 |
| Suppressing PAR ylation by 2′, 5′‐oligoadenylate synthetase 1 inhibits DNA damage‐induced cell death AA Kondratova, HJ Cheon, B Dong, EG Holvey‐Bates, M Hasipek, I Taran, ... The EMBO journal 39 (11), e101573, 2020 | 28 | 2020 |
| Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia Y Guan, M Hasipek, D Jiang, AD Tiwari, DR Grabowski, S Pagliuca, ... The Journal of clinical investigation 132 (4), 2022 | 20 | 2022 |
| Serum amyloid A1-13 T/C alleles in Turkish familial Mediterranean fever patients with and without amyloidosis. N Akar, M Hasipek, A Oztürk, E Akar, M Tekin Journal of Nephrology 19 (3), 318-321, 2006 | 14 | 2006 |
| Therapeutic targeting of protein disulfide isomerase PDIA1 in multiple myeloma M Hasipek, D Grabowski, Y Guan, RR Alugubelli, AD Tiwari, X Gu, ... Cancers 13 (11), 2649, 2021 | 11 | 2021 |
| TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics Y Guan, M Hasipek, AD Tiwari, JP Maciejewski, BK Jha Seminars in hematology 58 (1), 27-34, 2021 | 11 | 2021 |
| Tumour necrosis factor-alpha gene polymorphism (-308 GA) in Turkish pediatric thrombosis patients N Akar, M Hasipek Turk J Haematol 19 (1), 39-41, 2002 | 11 | 2002 |
| Genomic biomarkers predict response/resistance to lenalidomide in non-Del (5q) myelodysplastic syndromes YF Madanat, MA Sekeres, S Mukherjee, CM Hirsch, Y Guan, Y Nagata, ... Blood 132, 1797, 2018 | 8 | 2018 |
| Identification of a 4.9-kilo base-pair Alu-mediated founder SDHD deletion in two extended paraganglioma families from Austria AR Janecke, JE Willett-Brozick, C Karas, M Hasipek, J Loeffler-Ragg, ... Journal of human genetics 55 (3), 182-185, 2010 | 7 | 2010 |
| A machine learning model of response to hypomethylating agents in myelodysplastic syndromes N Radakovich, DA Sallman, R Buckstein, A Brunner, A Dezern, ... IScience 25 (10), 2022 | 5 | 2022 |
| A therapeutic strategy for preferential targeting of TET2 mutant and TET-dioxygenase deficient cells in myeloid neoplasms. Blood cancer discovery. 2021; 2: 146–61 Y Guan, AD Tiwari, JG Phillips, M Hasipek, DR Grabowski, S Pagliuca, ... Proc Natl Acad Sci US A 118, 2021 | 5 | 2021 |
| Role of oligoadenylate synthetases in myeloid neoplasia M Hasipek, Y Guan, D Grabowski, X Gu, Y Saunthararajah, R Silverman, ... Blood 136, 29-30, 2020 | 4 | 2020 |
| TET dioxygenase inhibition as a therapeutic strategy in TET2 mutant myeloid neoplasia Y Guan, AD Tiwari, JG Phillips, M Hasipek, D Grabowski, CM Kerr, ... Blood 134, 880, 2019 | 3 | 2019 |
| Predicting response to hypomethylating agents in patients with myelodysplastic syndromes (MDS) using artificial intelligence (AI) N Radakovich, MA Sekeres, CB Hilton, S Mukherjee, J Shreve, ... Blood 134, 2089, 2019 | 3 | 2019 |
| Eltrombopag creates a transient chemical phenocopy of TET2 loss of function that contributes to hematopoietic precursor expansion Y Guan, BJ Patel, M Hasipek, D Grabowski, H Awada, CM Kerr, ... Blood 134, 453, 2019 | 3 | 2019 |
